{"id":"NCT03686683","sponsor":"Dendreon","briefTitle":"Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer","officialTitle":"A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-18","primaryCompletion":"2023-03-10","completion":"2023-03-10","firstPosted":"2018-09-27","resultsPosted":"2024-10-08","lastUpdate":"2024-10-08"},"enrollment":532,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adenocarcinoma of the Prostate"],"interventions":[{"type":"BIOLOGICAL","name":"sipuleucel-T","otherNames":[]}],"arms":[{"label":"Treatment Group: Sipuleucel-T","type":"EXPERIMENTAL"},{"label":"Control Arm: Active Surveillance","type":"NO_INTERVENTION"}],"summary":"The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to participants followed on active surveillance as standard of care.","primaryOutcome":{"measure":"Efficacy of Sipuleucel-T Measured as the Percentage of Subjects Without Histological Reclassification (Gleason Group Upgrade).","timeFrame":"Once all participants have completed at least 3 years following randomization","effectByArm":[{"arm":"Treatment Group: Sipuleucel-T","deltaMin":108,"sd":null},{"arm":"Control Arm: Active Surveillance","deltaMin":48,"sd":null}],"pValues":[{"comp":"OG000","p":"0.4586"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":56,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":345},"commonTop":["Chills","Fatigue","Erectile dysfunction","Arthralgia","Headache"]}}